SMZ1 fundamentals
An in-depth look to Sino Biopharmaceutical Ltd. operating, investing, and financing activities
SMZ1 free cash flow for H2 23 is 414.7 M EUR. For 2023, SMZ1 free cash flow was 681.42 M EUR and operating cash flow was 847.65 M EUR.
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: EUR
TTM